These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

824 related articles for article (PubMed ID: 29853320)

  • 1. Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group.
    Rini BI; Hutson TE; Figlin RA; Lechuga MJ; Valota O; Serfass L; Rosbrook B; Motzer RJ
    Clin Genitourin Cancer; 2018 Aug; 16(4):298-304. PubMed ID: 29853320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group.
    Savard MF; Wells JC; Graham J; Dudani S; Steinharter JA; McGregor BA; Donskov F; Bjarnason GA; Vaishampayan UN; Hansen AR; Iafolla MAJ; Zanotti G; Huynh L; Chang R; Duh MS; Heng DYC
    Oncologist; 2020 May; 25(5):422-430. PubMed ID: 31971318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Ruiz-Morales JM; Swierkowski M; Wells JC; Fraccon AP; Pasini F; Donskov F; Bjarnason GA; Lee JL; Sim HW; Sliwczynsk A; Ptak-Chmielewska A; Teter Z; Beuselinck B; Wood LA; Yuasa T; Pezaro C; Rini BI; Szczylik C; Choueiri TK; Heng DY
    Eur J Cancer; 2016 Sep; 65():102-8. PubMed ID: 27487293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
    Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogeneity of Patients With Intermediate-Prognosis Metastatic Renal Cell Carcinoma Treated With Sunitinib.
    Sella A; Michaelson MD; Matczak E; Simantov R; Lin X; Figlin RA
    Clin Genitourin Cancer; 2017 Apr; 15(2):291-299.e1. PubMed ID: 27638198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
    [No Abstract]   [Full Text] [Related]  

  • 7. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
    Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis?
    Iacovelli R; De Giorgi U; Galli L; Zucali P; Nolè F; Sabbatini R; Fraccon AP; Basso U; Mosca A; Atzori F; Santini D; Facchini G; Fornarini G; Pasini F; Masini C; Massari F; Buti S; Sava T; Sacco C; Ricotta R; Sperduti I; Tortora G; Porta C
    Clin Genitourin Cancer; 2018 Oct; 16(5):355-359.e1. PubMed ID: 29803346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category.
    Davis ID; Xie W; Pezaro C; Donskov F; Wells JC; Agarwal N; Srinivas S; Yuasa T; Beuselinck B; Wood LA; Ernst DS; Kanesvaran R; Knox JJ; Pantuck A; Saleem S; Alva A; Rini BI; Lee JL; Choueiri TK; Heng DYC
    Eur Urol; 2017 Jun; 71(6):970-978. PubMed ID: 27771126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib.
    Beuselinck B; Vano YA; Oudard S; Wolter P; De Smet R; Depoorter L; Teghom C; Karadimou A; Zucman-Rossi J; Debruyne PR; Van Poppel H; Joniau S; Lerut E; Strijbos M; Dumez H; Paridaens R; Van Calster B; Schöffski P
    BJU Int; 2014 Jul; 114(1):81-9. PubMed ID: 24215209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world Experience With Sunitinib Treatment in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to Risk Score.
    Schmidinger M; Porta C; Oudard S; Denechere G; Brault Y; Serfass L; Costa N; Larkin J
    Clin Genitourin Cancer; 2020 Oct; 18(5):e588-e597. PubMed ID: 32586677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 2 Multicenter Single-Arm Study of Second-Line Axitinib in Favorable Risk Patients with Metastatic Renal Cell Carcinoma: FavorAx.
    Tsimafeyeu I; Borisov P; Abdelgafur A; Leonenkov R; Novikova O; Guseva I; Demchenkova M; Mikhailova N; Semenov A; Yurmazov Z; Sivunova I; Ramazanova M; Gamayunov S; Kosov D; Bratslavsky G
    Target Oncol; 2019 Feb; 14(1):33-38. PubMed ID: 30607698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma.
    Haanen JBAG; Larkin J; Choueiri TK; Albiges L; Rini BI; Atkins MB; Schmidinger M; Penkov K; Michelon E; Wang J; Mariani M; di Pietro A; Motzer RJ
    ESMO Open; 2023 Jun; 8(3):101210. PubMed ID: 37104931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, safety, and prognostic indicators of first-line sunitinib in patients with metastatic renal cell carcinoma: A single center experience.
    Abd Ghafar NK; Alip A; Ong TA; Yap NY; Saad M
    J Cancer Res Ther; 2018; 14(6):1303-1311. PubMed ID: 30488848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Wells JC; Stukalin I; Norton C; Srinivas S; Lee JL; Donskov F; Bjarnason GA; Yamamoto H; Beuselinck B; Rini BI; Knox JJ; Agarwal N; Ernst DS; Pal SK; Wood LA; Bamias A; Alva AS; Kanesvaran R; Choueiri TK; Heng DY
    Eur Urol; 2017 Feb; 71(2):204-209. PubMed ID: 27318422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study.
    Kubackova K; Melichar B; Bortlicek Z; Pavlik T; Poprach A; Svoboda M; Lakomy R; Vyzula R; Kiss I; Dusek L; Prausova J; Buchler T;
    Target Oncol; 2015 Dec; 10(4):557-63. PubMed ID: 25903462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-Reactive Protein Levels and Survival Following Cytoreductive Nephrectomy in 118 Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib: A Retrospective Study.
    Xu WH; Wang J; Huo DZ; Yin GC; Cao DL; Shi GH; Qu YY; Ye DW; Zhang HL
    Med Sci Monit; 2019 Nov; 25():8984-8994. PubMed ID: 31769434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Sunitinib in Patients With Favorable and Intermediate Risk Metastatic Renal Cell Carcinoma - Lithuanian National Cancer Institute Experience.
    Zalimas A; Urbonas V; Dabkeviciene D; Purvaneckas J; Ulys A; Jarmalaite S
    Anticancer Res; 2024 Jan; 44(1):213-219. PubMed ID: 38160003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A U.S. Food and Drug Administration-pooled Analysis of Frontline Combination Treatment Survival Benefits by Risk Groups in Metastatic Renal Cell Carcinoma.
    Lee D; Gittleman H; Weinstock C; Suzman D; Bloomquist E; Agrawal S; Brave M; Brewer J; Fallah J; Singh H; Tang S; Ibrahim A; Pazdur R; Beaver JA; Amiri-Kordestani L
    Eur Urol; 2023 Oct; 84(4):373-378. PubMed ID: 37271635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Stratification of the IMDC Intermediate Risk Group After Treatment With First-line Molecular-targeted Therapy for Metastatic Renal Cell Carcinoma.
    Takahara K; Ando R; Kanao K; Ito T; Miyake H; Sumitomo M; Yasui T; Shiroki R
    Anticancer Res; 2020 Aug; 40(8):4395-4400. PubMed ID: 32727768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.